ATE377011T1 - Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer - Google Patents
Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmerInfo
- Publication number
- ATE377011T1 ATE377011T1 AT00980679T AT00980679T ATE377011T1 AT E377011 T1 ATE377011 T1 AT E377011T1 AT 00980679 T AT00980679 T AT 00980679T AT 00980679 T AT00980679 T AT 00980679T AT E377011 T1 ATE377011 T1 AT E377011T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- compounds
- gamma
- hydroxy
- hiv protease
- Prior art date
Links
- 239000004030 hiv protease inhibitor Substances 0.000 title abstract 2
- 229940122440 HIV protease inhibitor Drugs 0.000 title 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000030507 AIDS Diseases 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940042443 other antivirals in atc Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16747899P | 1999-11-24 | 1999-11-24 | |
| US17705300P | 2000-01-20 | 2000-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE377011T1 true ATE377011T1 (de) | 2007-11-15 |
Family
ID=26863215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00980679T ATE377011T1 (de) | 1999-11-24 | 2000-11-21 | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6642237B1 (enExample) |
| EP (1) | EP1242426B1 (enExample) |
| JP (1) | JP2003514910A (enExample) |
| AT (1) | ATE377011T1 (enExample) |
| AU (1) | AU777824B2 (enExample) |
| CA (1) | CA2391643C (enExample) |
| CO (1) | CO5261497A1 (enExample) |
| DE (1) | DE60036961T2 (enExample) |
| ES (1) | ES2295068T3 (enExample) |
| PE (1) | PE20011025A1 (enExample) |
| WO (1) | WO2001038332A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| WO2001055326A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US7122376B2 (en) * | 2001-11-01 | 2006-10-17 | Facet Analytical Services And Technology, Llc | Calibration standards, methods, and kits for water determination |
| US7049146B2 (en) | 2000-11-14 | 2006-05-23 | Facet Analytical Services And Technology, Llc | Calibration standards, methods, and kits for water determination |
| AU2002305720A1 (en) * | 2001-05-30 | 2002-12-09 | Huening, Tracy, T. | Piperazine pentanamide hiv protease inhibitors |
| US6649761B2 (en) | 2001-05-30 | 2003-11-18 | Merck & Co., Inc. | Process for preparing piperazinepentaneamide HIV protease inhibitors |
| US6835860B2 (en) | 2002-02-01 | 2004-12-28 | Merck & Co., Inc. | Iodohydroxylation of olefins |
| US20040067216A1 (en) * | 2002-02-22 | 2004-04-08 | Karki Shyam B. | Hiv protease inhibitors supported on cation exchange resins for oral administration |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US20040131504A1 (en) * | 2002-09-17 | 2004-07-08 | Landers James P. | Remote temperature sensing of small volume and related apparatus thereof |
| US7199240B2 (en) * | 2002-12-11 | 2007-04-03 | Merck & Co., Inc. | Reductive alkylation of saturated cyclic amines |
| ES2571779T3 (es) * | 2002-12-13 | 2016-05-26 | Ym Biosciences Australia Pty | Inhibidores de cinasa a base de nicotinamida |
| TW574132B (en) * | 2003-04-14 | 2004-02-01 | Univ Nat Cheng Kung | Integrated microfluidic electro-spray chip system and the analysis method thereof |
| US7161015B1 (en) * | 2005-09-08 | 2007-01-09 | The United States Of America As Represented By The Secretary Of The Navy | Method of making 2-furylalkylketones |
| JP2006316049A (ja) * | 2006-04-11 | 2006-11-24 | Tanabe Seiyaku Co Ltd | ２，２−ジアルコキシエチルアミン化合物およびその製造方法 |
| JP2012528160A (ja) | 2009-05-27 | 2012-11-12 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖプロテアーゼ阻害薬 |
| EP3970702A1 (en) | 2009-10-26 | 2022-03-23 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
| WO2011120153A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| EP2630133A1 (de) | 2010-10-22 | 2013-08-28 | Bayer Intellectual Property GmbH | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| EP2632895B1 (en) | 2010-10-28 | 2018-10-03 | Merck Canada Inc. | Hiv protease inhibitors |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| JP2014527973A (ja) | 2011-09-23 | 2014-10-23 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 非生物的な植物ストレスに対する作用剤としての４−置換１−フェニルピラゾール−３−カルボン酸誘導体の使用 |
| EP2771332B1 (en) | 2011-10-26 | 2016-06-29 | Merck Canada Inc. | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS |
| AU2013315833A1 (en) | 2012-09-11 | 2015-03-05 | Merck Canada Inc. | HIV protease inhibitors |
| WO2015013835A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp. | Piperazine derivatives as hiv protease inhibitors |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| US9834526B2 (en) | 2013-12-19 | 2017-12-05 | Merck Sharp & Dohme Corp. | HIV protease inhibitors |
| EP3083609B1 (en) | 2013-12-19 | 2018-08-15 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| EP3113780B1 (en) | 2014-03-06 | 2019-08-14 | Merck Sharp & Dohme Corp. | Hiv protease inhibitors |
| US10138255B2 (en) | 2014-03-10 | 2018-11-27 | Merck Sharp & Dohme Corp. | Piperazine derivatives as HIV protease inhibitors |
| EP2944955A1 (en) * | 2014-05-13 | 2015-11-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benchmark for LC-MS systems |
| BR112016030604B8 (pt) * | 2014-07-08 | 2022-08-23 | Dow Agrosciences Llc | Processo para preparação de ácidos 3- hidroxipicolínicos |
| CN104311479B (zh) * | 2014-09-15 | 2016-06-15 | 西华大学 | 3,5-二碘-4-羟基吡啶的合成 |
| TW201730188A (zh) * | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| WO2019175464A1 (en) | 2018-03-14 | 2019-09-19 | Orion Corporation | Compounds useful as inhibitors of sodium-calcium exchanger (ncx) |
| AR114422A1 (es) | 2018-03-30 | 2020-09-02 | Syngenta Participations Ag | Compuestos herbicidas |
| JP2022507262A (ja) | 2018-11-12 | 2022-01-18 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 除草化合物 |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL103613A (en) | 1991-11-08 | 1999-05-09 | Merck & Co Inc | Hiv protease inhibitors process and intermediats for their preparation and pharmaceutical compositions containing them |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| IL110255A (en) | 1993-07-16 | 1998-12-06 | Merck & Co Inc | Formation and resolution of 2-tert-butylcarboxamido-piperazine |
| US5455351A (en) * | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
| WO1995016688A1 (en) | 1993-12-15 | 1995-06-22 | Merck & Co., Inc. | Hiv protease inhibitors |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| TW438799B (en) | 1997-05-29 | 2001-06-07 | Merck & Co Inc | HIV protease inhibitor |
| WO1999033795A1 (en) | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
-
2000
- 2000-11-21 EP EP00980679A patent/EP1242426B1/en not_active Expired - Lifetime
- 2000-11-21 CA CA002391643A patent/CA2391643C/en not_active Expired - Fee Related
- 2000-11-21 AU AU17909/01A patent/AU777824B2/en not_active Ceased
- 2000-11-21 US US09/718,223 patent/US6642237B1/en not_active Expired - Fee Related
- 2000-11-21 DE DE60036961T patent/DE60036961T2/de not_active Expired - Lifetime
- 2000-11-21 WO PCT/US2000/032089 patent/WO2001038332A1/en not_active Ceased
- 2000-11-21 JP JP2001540095A patent/JP2003514910A/ja not_active Withdrawn
- 2000-11-21 AT AT00980679T patent/ATE377011T1/de not_active IP Right Cessation
- 2000-11-21 ES ES00980679T patent/ES2295068T3/es not_active Expired - Lifetime
- 2000-11-23 CO CO00089726A patent/CO5261497A1/es not_active Application Discontinuation
- 2000-11-24 PE PE2000001259A patent/PE20011025A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2295068T3 (es) | 2008-04-16 |
| AU1790901A (en) | 2001-06-04 |
| EP1242426A1 (en) | 2002-09-25 |
| CA2391643C (en) | 2010-01-12 |
| EP1242426B1 (en) | 2007-10-31 |
| JP2003514910A (ja) | 2003-04-22 |
| PE20011025A1 (es) | 2001-10-12 |
| DE60036961T2 (de) | 2008-08-28 |
| AU777824B2 (en) | 2004-11-04 |
| CO5261497A1 (es) | 2003-03-31 |
| US6642237B1 (en) | 2003-11-04 |
| WO2001038332A1 (en) | 2001-05-31 |
| DE60036961D1 (de) | 2007-12-13 |
| CA2391643A1 (en) | 2001-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60036961D1 (de) | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer | |
| ATE175412T1 (de) | Hiv-protease-inhibitoren | |
| EA200300449A1 (ru) | Аза- и полиаза-нафталинилкарбоксамиды, полезные в качестве ингибиторов вич-интегразы | |
| DE60128936D1 (en) | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer | |
| DE60124577D1 (en) | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer | |
| LU91428I2 (fr) | ISENTRESS- raltégravir | |
| MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
| ATE252081T1 (de) | Neue hiv-protease-inhibitoren | |
| DE69430385D1 (de) | Hiv-proteaseinhibitoren | |
| PT617968E (pt) | Inibidores de protease de hiv em combinacao farmaceutica para tratamento de sida | |
| WO1996000068A3 (en) | Combination therapy for hiv infection | |
| DK0774969T3 (da) | HIV-proteaseinhibitor kombination | |
| WO2002096359A3 (en) | Piperazine pentanamide hiv protease inhibitors | |
| FI970565A0 (fi) | HIV-proteaasia inhiboiva yhdistelmä |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |